P53 as a prognostic factor for stage III serous adenocarcinoma of the ovary

Anticancer Research

Volumn 19, Issue 3 B, 1999, Pages 2387-2389

  Daponte, A ^a   Guidozi, F ^b   Tiltman, A J ^b   Marineanu, A ^b   Taylor, L ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b NONE

Author keywords

Ovarian cancer; p53; Prognosis

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DIAMINOBENZIDINE; MONOCLONAL ANTIBODY; MUTANT PROTEIN; PROTEIN P53; REAGENT;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CYSTADENOCARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; GENES, P53; HUMANS; MUTATION; NEOPLASM STAGING; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032781591     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Santoso J T, Tang D, Lane SB et al: Adenovirus-based p53 gene therapy in ovarian cancer. Gynecol Oncol 9: 171 -178, 1995.
2. Mujoo K, Maneval D C, Anderson SG et al: Adenoviral-mediated p53 suppressor gene therapy of human ovarian carcinoma. Oncogene 12: 1617-1623, 1996.
3. ̃ O. Immunohistochemical analysis of p53 in gynaecologic tumours. Am J Clin Pathol 102: 665-670, 1994.
4. Hollstein M, Sidransky D, Vogelstein B, Harris C C. p53 Mutations in human cancers. Science 1991; 253: 49-53.
5. Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O, Oren M. Wild type p53 can Inhibit oncogene mediated focus formation. Proc Natl Acad Sci USA 86: 8763-8767, 1989.
6. Mcllwrath A J, Vasey P A, Ross G M, Brown R. Cell cycle arrests and radio-sensitivity of human tumour cell lines: Dependence on wild-type p53 for radiosensitivity. Cancer Res 54: 3718-3722, 1994.
7. Lowe S W, Bodis S, McClatchey A, Remington L, Ruley H E, Fisher D E, Housman D E, Jacks T. p53 Status and the efficacy of cancer therapy in vivo. Science; 266: 807-810.
8. Dowell S P, Hall P A, The clinical relevance of the p53 tumour suppressor gene. Cytopathology 5: 133-145, 1994.
9. Wynford_Thomas D. p53 In tumour pathology: can we trust immunocytochemistry? [Editorial] J Pathol 166: 329-330, 1992.
10. Baas I O, Mulder J W R, Offerhaus G J A, Vogelstein B, Hamilton S R. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Path 172: 5-12, 1994.
11. Henriksen R, Strang P, Wilander E, Backstrom T, Tribukait B, Oberg K. p53 Expression in epithelial ovarian neoplasms: relationships to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gynecol Oncol 53: 301-306, 1994.
12. Nowa K, Itoh M, Murase T, Morishita S, Itoh N, Mori H, Tamaya T. Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance. Br J Cancer 70: 1191 -1197, 1994.
13. Yaginuma Y, Westphal H. Abnormal structure of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 52: 4196-4199, 1992.
14. Kiyokawa T. Alteration of p53 in ovarian cancer: its occurrence and maintenance in tumour progression. Int J Gynecol Pathol 13: 311 -318, 1994.
15. Klemi P J, Takahashi S, Joensuu H, Kiiholma P, Narimatsu E, Mori M. Immunohistochemical detection of p53 protein in borderline and malignant serous ovarian tumours. Int J Gynecol Pathol 13: 228-233, 1994.
16. Levesque M A, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, Diamandis E P. Mutant p53 protein over expression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 75: 1327-1338, 1995.